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To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and
leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer
(MCC). A total of 283 chemotherapy-naı ¨ve patients with MCC were enrolled (FOLFIRI arm: n¼146; FOLFOXIRI arm: n¼137). In
the FOLFOXIRI arm, CPT-11 (150mgm
 2) was given on d1, L-OHP (65mgm
 2)o nd 2, LV (200mgm
 2) on days 2 and 3 and 5-FU
(400mgm
 2 as i.v. bolus and 600mgm
 2 as 22h i.v. continuous infusion) on days 2 and 3. In the FOLFIRI arm, CPT-11 (180mgm
 2)
was given on d1 whereas LV and 5-FU were administered in the same way as in the FOLFOXIRI regimen. Both regimens were
administered every 2 weeks. There was no difference in terms of overall survival (median OS: 19.5 and 21.5 months, for FOLFIRI and
FOLFOXIRI, respectively; P¼0.337), median time to disease progression (FOLFIRI: 6.9 and FOLFOXIRI: 8.4 months; P¼0.17),
response rates (33.6 and 43% for FOLFIRI and FOLFOXIRI, respectively; P¼0.168). Patients treated with FOLFOXIRI had a
significantly higher incidence of alopecia (P¼0.0001), diarrhoea (P¼0.0001) and neurosensory toxicity (P¼0.001) compared with
patients treated with FOLFIRI. The present study failed to demonstrate any superiority of the FOLFOXIRI combination compared
with the FOLFIRI regimen, although the observed median OS is one of the best ever reported in the literature.
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Colorectal cancer (CRC) is the second most common cancer in
Europe (Ferlay et al, 1999), accounting for 8% of all malignant
tumours in adults (Parkin et al, 2005), and the third in the USA,
with approximately 145000 new cases expected in 2005 (American
Cancer Society, 2005). Despite a macroscopically curative surgical
resection in 70–80% of patients, almost half of them will develop
local recurrence or/and metastatic disease and will die of the
disease (Kohne et al, 1998).
Since 1957 and until the last decade, 5-fluorouracil (5-FU) was
the only active cytotoxic agent against advanced CRC. Further-
more, there is no internationally accepted ‘standard’ 5-FU/
leucovorin (LV) regimen; the monthly 5-day i.v. bolus North
Central Treatment Group, ‘Mayo Clinic’ regimen, is commonly
used (Poon et al, 1989); however, in Europe, a biweekly regimen
combining bolus and infusional 5-FU modulated by LV (‘de
Gramont’ schedule) is commonly used in the previous years.
Recent studies have demonstrated that the de Gramont regimen
was more effective and had a better safety profile than the LV/FU
bolus regimen (de Gramont et al, 1997).
Irinotecan (CPT-11, Campto
s, Pfizer Pharmaceuticals, New
York, NY, USA) is a hemi-synthetic, water-soluble derivative of the
plant alkaloid camptothecin. After conversion in the liver to its
active metabolite, SN-38, CPT-11 acts by inhibiting the eucariotic
enzyme DNA-topoisomerase I (Hsiang et al, 1989; Tanizawa et al,
1994). Phase III studies in patients with metastatic CRC (MCC)
clearly demonstrated a significant survival advantage for irinotecan
combined with LV/FU, compared with LV/FU alone (Douillard
Received 5 October 2005; revised 19 January 2006; accepted 23 January
2006; published online 28 February 2006
*Correspondence: Dr J Souglakos; E-mail: georgsec@med.uoc.gr
British Journal of Cancer (2006) 94, 798–805
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
set al, 2000; Saltz et al, 2000). These studies established irinotecan-
based chemotherapy as the ‘standard of care’ (FOLFIRI in Europe
and IFL in the United States) and therefore became the preferred
comparator regimens for further phase III trials.
The 1,2 diaminocyclohexane (DACH) platinate oxaliplatin
(L-OHP; Eloxatin, Sanofi-Aventis Inc., Paris, France) differs from
previously developed cisplatin and carboplatin in that it does not
present free amino groups linked to platinum, but rather a cyclic,
bulky, rigid structure. 1,2 Diaminocyclohexane platinates combine
with DNA to form adducts resistant to DNA repair and replicative
bypass (Raymond et al, 1998). While L-OHP seems to form the
same type of lesions as cisplatin and at the same sites on DNA,
L-OHP-induced adducts are more effective at inhibiting DNA
synthesis (Rixe et al, 1996). Moreover, the only different resistance
mechanisms between cisplatin and L-OHP are defects in mismatch
repair and enhanced replicative bypass (Bleiberg, 1998). A
randomised study has shown that LVFU2 in combination with
L-OHP (FOLFOX4) was associated with a prolonged progression-
free survival compared with LVFU2 (de Gramont et al, 2000).
Moreover, FOLFOX 4 was associated with an improved median
overall survival (OS) when compared with IFL (irinotecan in
combination with LV/FU given i.v. bolus) (Goldberg et al, 2004).
In vitro models suggest schedule-dependent cytotoxic interac-
tions for the combination of thymidylate synthase inhibitors with
SN-38 and L-OHP; indeed, synergistic effects were demonstrated
only when SN-38 was started 24–48h before the L-OHP/5-FU/LV
exposure in WIDR and SW620 human CRC cell lines (Fischel et al,
1999). The efficacy and tolerance of the FOLFOXIRI regimen has
been recently reported; the observed response rates (RR) were 58.1
and 69%, the time to tumour progression (TTP) 11 and 10.4
months and the estimated OS 22.5 and 26.5 months in the Greek
and the Italian phase II studies, respectively (Falcone et al, 2002;
Souglakos et al, 2002).
Based on these promising results a multicentre randomised
phase III study was conducted by the Gastrointestinal Committee
of the Hellenic Oncology Research Group (HORG) in order to
evaluate the efficacy and safety of the FOLFOXIRI regimen in
comparison with the standard combination of FOLFIRI regimen as
first-line treatment in patients with advanced CRC.
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically documented and measurable metastatic
adenocarcinoma of the colon or rectum were enrolled. Previous
chemotherapy for metastatic disease was not allowed. Patients
who had received prior adjuvant 5-FU-based chemotherapy were
eligible if they had remained free of disease for at least 6 months
after the completion of adjuvant therapy. Patients with operable
metastatic disease were excluded from the study. Other eligibility
criteria were: age X18 years, performance status (ECOG) 0–2; at
least one bidimensionally measurable lesion of X2cm; a life
expectancy of at least 3 months; adequate haematologic parameters
(absolute neutrophil count X1.5 10
9l
 1 and platelets
X100 10
9l
 1); creatinine and total bilirubin p1.25 times the
upper limit of normal; aspartate and alanine aminotransferases
p3.0 times the upper limit of normal; absence of active infection
or malnutrition (loss of more than 10% of body weight); absence of
a second primary tumour other than nonmelanoma skin cancer or
in situ cervical carcinoma. Patients treated with palliative radio-
therapy had to have measurable metastatic disease outside the
irradiation fields. Patients with severe cardiac dysfunction, liver
metastases involving more than 50% of the liver parenchyma,
chronic diarrhoea, or prior irradiation affecting more than 30% of
the active bone marrow were excluded. The study was approved by
the Ethics and Scientific Committees of each participating centre.
All patients gave written informed consent in order to participate
in the study.
Chemotherapy
Patients were centrally randomised to receive either the FOLFIRI
or the FOLFOXIRI regimen. Patients randomised in the FOLFIRI
regimen (arm A) received CPT-11 at the dose of 180mgm
 2 as a
30min i.vinfusion on day 1; LV was given at the dose of
200mgm
 2 as a 2-h i.v. infusion, followed by 5-FU 400mgm
 2
as i.v. bolus, and then, 600mgm
 2 as a 22-h continuous i.v.
infusion, on days 1 and 2. Patients randomised in the FOLFOXIRI
regimen (arm B) received CPT-11 at the dose of 150mgm
 2 as a
30min i.v. infusion on day 1; LV was given at the dose of
200mgm
 2 as a 2-h i.v. infusion, followed by 5-FU 400mgm
 2 as
i.v. bolus, and then, 600mgm
 2 as a 22-h continuous i.v. infusion,
on days 2 and 3. Oxaliplatin was administered on day 2 at the dose
of 65mgm
 2 as a 2-h i.v. infusion in parallel with LV but using
different lines (Figure 1). Routine antiemetic prophylaxis with a
5-hydroxytryptamine-3-receptor antagonist was used in both
study groups. Treatment was administered every 2 weeks until
disease progression or unacceptable toxicity, or until the patient
declined further treatment.
Patients were assessed for toxicity before each cycle using the
National Cancer Institute Common Toxicity Criteria (National
Cancer Institute, 1999). Chemotherapy was delayed until recovery
if neutrophils were o1.5 10
9l
 1 or platelets less than
100 10
9l
 1 or for significant persisting nonhaematologic toxicity.
CPT-11 was administered according to the guidelines used for
CPT-11 monotherapy, including recommendations for using
atropine and loperamide (Wadler et al, 1998). Peripheral sensory
neuropathy was graded according to the L-OHP-specific scale
modified from Caussanel (Caussanel et al, 1990): paresthaesias/
dysethaesias of short duration with complete recovery before the
next cycle (grade 1); paresthaesias/dysethaesias persisting between
two cycles without functional impairment (grade 2); paresthaesias/
dysethaesias with functional impairment (grade 3).
Doses of all drugs were reduced by 15% in subsequent cycles
in case of grade 4 neutropenia or grade 3–4 thrombocytopenia
lasting for more than 3 days or in case of febrile neutropenia. No
prophylactic administration of granulocyte colony-stimulating
factor (G-CSF) was allowed. Granulocyte colony-stimulating factor
was used for the treatment of febrile neutropenia. Doses of CPT-11
and 5-FU were reduced by 15% in subsequent cycles in case of
grade 3 or 4 diarrhoea. The 5-FU dose was reduced in case of
grades 3–4 stomatitis or dermatitis. Oxaliplatin dose was reduced
by 15% in cases of persistent (X14 days) paresthaesia or
temporary (7–14 days) painful paresthaesia or functional impair-
ment. In cases of persistent (X14 days) painful paresthaesia or
functional impairment, L-OHP was omitted in subsequent cycles
from the regimen until recovery.
Patient evaluation
Pretreatment evaluation included a detailed medical history and
physical examination, a complete blood cell count (CBC) with
differential and platelet count, blood chemistry, serum levels of
carcinoembryonic antigen and computed tomography scans of the
chest and abdomen. Pretreatment evaluation had to be performed
within 2 weeks prior to study entry. During treatment, a CBC with
differential and platelets count was performed weekly and in case
of grades 3–4 neutropenia or thrombocytopenia or febrile
neutropenia it was performed daily until haematologic recovery.
In addition, patients were clinically assessed and blood chemistry
was performed before each treatment cycle. Response to treatment
was evaluated every 2 months (four chemotherapy cycles) or
sooner if clinically indicated.
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sThe Response Evaluation Criteria in Solid Tumors (RECIST)
were used to assess tumour responses (Therasse et al, 2000).
Complete response required that all disease disappear without new
lesions. Partial response required at least a 50% reduction in the
sum of the products of the longest perpendicular diameters of all
measurable lesions. Disease progression required 25% or greater
increase in measurable tumour or an increase in tumour size in
patients whose lesions did not meet the criteria for measurable
disease. After partial response, tumour measurements exceeding
50% of the maximal extent of a previously observed reduction
constituted progression. Any new lesion also constituted progres-
sion. Patients who did not meet the definitions of response or
progression were classified as having stable disease.
The duration of response was measured from the first
documentation of response to disease progression. The TTP was
determined by the interval between the initiation of treatment and
the date when disease progression was first documented or the
date of death from any cause. Overall survival was measured from
the date of treatment initiation to the date of death. The follow-up
time was measured from the day of first treatment administration
to the time of the present analysis (for patients still alive).
Statistical considerations
Randomisation was performed using a minimisation technique
(Pocock and Simon, 1975), stratifying patients by centre, prior
adjuvant chemotherapy (yes or not) and ECOG performance status
(0–1 vs 2). The primary end point of the study was OS. Secondary
end points were TTP, RR and tolerance. The study was designed
for two sided log-rank test to have 80% power to detect a 25%
improvement in survival for the experimental arm, based on the
assumption that OS would be 17 months in the standard arm
(FORFIRI) (Douillard et al, 2000) and 22.5 months for the
experimental arm (FOLFOXIRI) (Souglakos et al, 2002) (type I
error 5%, type II error 20%). Using the Freedman’s formula, 136
patients per arm were required with the assumption that the
accrual period would last 48 months (Freedman, 1982). An interim
analysis using O’Brien–Fleming boundaries after 50% of patients
progressed was planned (O’Brien and Fleming, 1979). The
Kaplan–Meier method was used to estimate survival and PFS
curves, and the log-rank test was used to compare the curves
(Kaplan and Meier, 1958). Cox’s proportional hazards modelling
was used to calculate hazard ratios (HR) and confidence intervals
(CIs;) (Cox, 1972). w
2 tests were used to compare toxicity and
confirmed RR. P-values o0.05 were considered statistically
significant for all comparisons. All randomised patients were
included in an intention-to-treat analysis; patients who canceled
before the initiation of therapy were excluded from toxicity
analyses (Figures 2 and 3).
RESULTS
Patients characteristics
From October 2000 to December 2004, 285 patients (147 in arm A
and 138 in arm B) with MCC were randomly assigned to receive
front-line chemotherapy at 11 institutions and received at least one
chemotherapy cycle. Two patients, one in each arm, received no
study treatment because consents were withdrawn. Baseline
characteristics of the remaining 283 patients are shown in Table 1.
Almost half of the patients in both arms were X65 years old; PS of
0–1 had 89% of patients in each arm; liver metastases were present
in 70 and 72% of the arm A and B patients, respectively, whereas
16.4 and 24.6% of them, had X3 involved sites. In 43 and 48% of
the arm A and B patients, respectively, metastases were
synchronous to diagnosis of the primary tumour. Overall
approximately one-quarter of the patients in each arm were
classified as high risk according to the Kohne prognostic index
(Ko ¨hne et al, 2002).
Efficacy
With a median follow-up period of 26 months (range, 1–62
months), 85% of patients had disease progression and 62% had
CPT-11 180 mg m–2
 30 min
LV 200 mg m–2
2 h    
5-FU 600 mg m–2
22 h
LV 200 mg m–2
2 h
5-FU 600 mg m–2
22 h
5-FU 400 mg m–2 
Bolus
d1
d2
Arm A 
Arm B 
d1
d2
d3
CPT-11 150 mg m–2
30 min  
LOHP 65 mg m–2
2 h
LV 200 mg m–2
2 h
LV 200 mg m–2
2 h
  
5-FU 600 mg m–2
22 h
  
5-FU 600 mg m–2
22 h
5-FU 400 mg m–2
Bolus 
Figure 1 Chemotherapy regimens (A) FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) and (B) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and
irinotecan).
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sdied. The OS was not significantly different between the two arms
(FOLFIRI arm: 19.5 months (range: 1.0–55.7)) and (FOLFOXIRI
arm: 21.5 months (range 1–62.3)), (P¼0.337). The probability of
1- and 2-years survival was 64 and 34% in arm A and 67 and 43%
in arm B, respectively (Figure 1). Multivariate analysis revealed
that independent prognostic factors for decreased survival were PS
of 2 and nonresponse to treatment with HR 2.5 (95% CI: 1.701–
3.703; P¼0.0001) and 2.102 (95% CI: 1.598–2.765; P¼0.0001),
respectively. In contrast age, treatment arm and prior adjuvant
chemotherapy was not significant factors for the patients’
outcome. In the FOLFIRI group the OS was 20 months for patients
with PS 0–1 and 6.4 months for patients with PS of 2 (P¼0.03);
in the FOLFOXIRI group the OS was 24 moths for the patients
with PS of 0–1 and 6.6 months for the patients with PS of 2
(P¼0.0001). There was no statistical difference in terms of OS in
young or aged patients irrespectively of the received regimen
(FOLFIRI arm: o65 years: OS 19.9 months; X65 years: OS 16.9
months; P¼0.452; FOLFOXIRI arm: o65 years: OS 22.1 months;
X65 years: OS19.9 months; P¼0.263). Patients enrolled in the
FOLFIRI arm had a significantly better OS when received second-
line chemotherapy (median OS 21 months; range: 15.9–55.7)
compared to those who did not (median OS 12.2 months;
range: 7.82–16.64) (P¼0.016); this was not the case for
patients who were enrolled to the FOLFOXIRI arm (median
OS 23 months; range: 17.6–62.3 for those who received second-
line chemotherapy) vs (median OS 19.5 months; range: 13.4–25.5
for those who did not received second-line chemotherapy)
(P¼0.942).
Median time to disease progression (TTP) was 6.9 months (95%
CI: 6.0–7.7 months; range: 1.0–39.3) for patients receiving
FOLFIRI and 8.4 months (95% CI: 7–10.2 months; range: 1.0–
32.3) for patients receiving FOLFOXIRI with a HR of 0.83 (95% CI:
0.64–1.08; P¼0.17) (Figure 4). In the FOLFIRI arm, TTP was 7.1
months (range: 1–39.3) for patients with PS of 0–1 and 2 months
(range: 1–10.7) for patients with PS of 2 (P¼0.0001); in the
FOLFOXIRI arm, TTP was 9.7 (range: 1.0–32.3) and 4.1 (range:
1.0–15.9) months for patients with PS of 0–1 and 2, respectively
(P¼0.0047). In Cox’s multivariate analysis PS of 2 (HR: 1.857,
95% CI: 1.217–2.834, P¼0.004) and no response to treatment
(HR: 2.166, 95% CI: 1.553–3.020, P¼0.0001) but not age were
emerged as independent prognostic factors for TTP. Although it
was a trend for lower TTP prior adjuvant chemotherapy it was not
a significant factor for patient’s outcome. Age and treatment arm
were not important prognostic factors for the TTP.
288 patients eligible
for the study
285 patients
randomised
Two patients found ineligible 
one patient refused to sign 
informed consent
147 patients assigned to  
FOLFIRI regimen 
138 patients assigned to
FOLFOXIRI regimen 
146 patients were  
analysed
137 patients were
analysed
One patient did not receive 
study treatment 
One patient did not receive 
study treatment 
Reasons for treatment discontinuation
Disease progression: 126 
Toxicity: 7 
Toxic death: 2 
Patient refusal: 3
Reasons for treatment discontinuation
Disease progression: 114
Toxicity: 16 
Toxic death: 2 
Patient refusal: 1
Figure 2 Trial profile.
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sResponse to treatment
Five (3.4%) CRs were observed in the FOLFIRI arm and nine
(6.5%) in the FOLFOXIRI arm; in addition 44 (30.2%) and 50
(36.5%) patients enrolled in the FOLFIRI and FOLFOXIRI arm,
respectively, experienced a PR for an overall RR of 33.6% for
FOLFIRI and 43% for FOLFOXIRI (P¼0.168). In all, 39 (26.7%)
patients treated with FOLFIRI and 43 (31.3%) patients treated with
FOLFOXIRI presented stabilisation of the disease while 58 (39.7%)
and 35 (25.5%) patients, respectively, progressed under treatment.
The median time of response duration was 9 (range: 1–27.1) and
9.7 months (range, 1–34.6) (P¼0.44) in the FOLFIRI and the
FOLFOXIRI arm, respectively.
Secondary metastasectomy was performed in six (4%) patients
treated with FOLFIRI and 14 (10%) patients treated with
FOLFOXIRI (P¼0.08). Six patients (three in each arm) underwent
resection of lung metastases and 14 patients of liver lesions (three
in the FOLFIRI and 11 in the FOLFOXIRI arm). R0 resection could
be realised in all patients with lung lesions and in 11 patients with
liver metastases (two in arm A and nine in arm B).
Compliance with the treatment
A total of 1212 treatment cycles were administered in the FOLFIRI
arm and 1179 in the FOLFOXIRI arm. The median number of
cycles was nine (range 1–22) and 10 (range 1–20) per patient
treated with the FOLFIRI and the FOLFOXIRI regimen, respec-
tively.
A total of 101 (8.3%) chemotherapy courses were delayed in
the FOLFIRI and 166 (14%) in the FOLFOXIRI arm (P¼0.04); the
median duration of delay was 4 days (range, 1–14) in each arm.
The reasons of delay were haematologic (FOLFIRI: n¼44, 4.0%;
FOLFOXIRI: n¼74, 6.0%), nonhaematologic (FOLFIRI: n¼9,
1%; FOLFOXIRI: n¼23, 2.0%) or both (FOLFIRI: n¼4, 0.3%;
FOLFOXIRI: n¼14, 1%) toxicity; 54 (4.0%) courses in the
FOLFIRI and 55 (5.0%) in the FOLFOXIRI arm were delayed
because of reasons unrelated to disease or treatment (i.e. pending
imaging studies for response evaluation). The median interval
between cycles was 16 days in both treatment arms. Dose reduction
was required in 40 (3.0%) cycles in the FOLFIRI arm and 87 (7.0%)
cycles in the FOLFOXIRI arm (P¼0.001). In all, 10 (7.0%) patients
discontinued treatment in the FOLFIRI arm and 16 (12.0%) in the
FOLFOXIRI arm (P¼0.296). The reasons for treatment disconti-
nuation were haematologic (FOLFIRI: n¼22 cycles, 2.0%;
Table 1 Patients characteristics
FOLFIRI (n¼146) FOLFOXIRI (n¼137)
Characteristics n % n %
Age
Median (range) 66 (39–84) 66 (25–82)
X65 years 82 56 75 55
Sex
Male 82 58 76 55
Female 61 42 61 45
Performance status (ECOG)
05 5 3 8 4 9 3 6
17 4 5 1 7 3 5 3
21 7 1 1 1 5 1 1
Localisation
Colon 110 75 100 73
Rectum 36 25 37 27
Sites of disease
Liver 102 70 99 72
Lung 46 32 42 31
Other 63 43 61 46
Number of metastatic sites
15 9 4 0 5 5 4 0
26 3 4 3 5 7 4 2
X32 4 1 6 2 5 1 8
Median (range) 2 (1–4) 2 (1–6)
Metastases
Synchronous 63 43 66 48
Metachronous 83 57 70 52
Kohne prognostic index
Low risk 54 37 44 32
Intermediate risk 57 39 56 41
High risk 35 24 37 27
Prior therapy
Adjuvant chemotherapy 48 33 49 36
Adjuvant 18 17
Chemoradiotherapy 12 12
Months
%
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f
 
T
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P
Log-rank test: 0.175 
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Figure 4 Kaplan–Meier time to tumour progression (TTP) of patients
treated with FOLFIRI and FOLFOXIRI.
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Figure 3 Kaplan–Meier overall survival of patients treated with FOLFIRI
and FOLFOXIRI.
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cycles, 1.4%; FOLFOXIRI: n¼47, 4.0%) toxicity. The delivered
relative dose intensity was 85% for CPT-11, 84% for L-OHP and
88% for 5-FU/LV of the protocol-planned doses in the FOLFOXIRI
arm and 90% for CPT-11 and 92% for 5-FU/LV in the FOLFIRI
arm.
Toxicity
Patients treated with the FOLFOXIRI regimen had a significantly
higher incidence of severe alopecia (P¼0.0001), diarrhoea
(P¼0.001) and neurosensory disorders (P¼0.001) compared with
patients treated with FOLFIRI (Table 2). There was no difference in
the incidence of severe (grade 3/4) haematological toxicity. There
were two treatment-related deaths in the FOLFIRI arm and two in
the FOLFOXIRI arm. All four treatment-related deaths were due to
febrile neutropenia combined with diarrhoea. The death rates
within the first 60 days of treatment were 2.7% (95% CI, 1.1–4.6%)
for patients treated with the FOLFIRI regimen and 2.9% (95% CI,
1.3–5.3%) for those treated with the FOLFOXIRI regimen.
Patients with PS of 2 presented a significantly higher incidence
of grade 3/4 neutropenia (P¼0.001), diarrhoea (P¼0.001), fatigue
(P¼0.0001) and febrile neutropenia (P¼0.02) in comparison
with patients with PS of 0–1 in both treatment arms. In addition
patients older than 65 years showed a significantly higher
incidence of grade 3/4 diarrhoea in comparison with younger
patients in both treatment groups (P¼0.005 and 0.017, for
FOLFIRI and FOLFOXIRI arm, respectively). There was no
difference in terms of grade 3/4 haematologic or nonhaematologic
toxicity for patients who had previously received adjuvant
chemotherapy or/and radiotherapy.
Second-line treatment
Chemotherapy regimens administered after first-line therapy are
shown in Table 3. Although second-line treatments were not
specified by the protocol we requested that therapies administered
after progression on protocol therapy must be reported. A higher
proportion (70%) of patients treated with FOLFIRI received
second-line treatment; the majority of them were treated with
L-OHP-based chemotherapy (XELOX or FOLFOX regimen).
Conversely, relatively fewer patients (58%) treated with front-line
FOLFOXIRI received second-line treatment compared with those
who were treated with FOLFIRI (P¼0.041). A small proportion of
these patients received second-line CPT-11 and Cetuximab.
DISCUSSION
This is the first randomised study comparing the efficacy of the
combination of all active drugs against CRC (CPT-11, L-OHP, 5-FU
and LV) as first-line treatment of patients with MCC. Although the
observed OS (median 21.5 months) for the FOLFOXIRI arm is one
of the longest observed in a randomised multicentre trial using
any combination regimen for first-line therapy, the difference
could not reach statistical significance. In addition, there was no
difference between the two arms concerning the secondary end
points of the study which were the TTP and the RR, although there
is a trend for longer TTP with the triple drug regimen (HR:0.83;
P¼0.17; Figure 4).
The median OS achieved with the FOLFOXIRI regimen was
similar with that reported from our group in a previous phase II
study (Souglakos et al, 2002) and therefore was used for the
statistical design of this trial. On the other hand, the OS in the
standard (FOLFIRI) arm was 19.5 months, 2.5 months more than
that reported in the initial FOLFIRI randomised trial (Douillard
et al, 2000), which was also used for the statistical design of our
trial. In the present study, the median age and the proportion of
patients’ X65 years old were higher in comparison with that
reported in the initial FOLFIRI trial (10). In addition, our study
enrolled patients 475 years old, a practice which was relatively
unusual in the previous randomised studies (Douillard et al, 2000;
Tournigand et al, 2004). Both the subgroup and the multivariate
analyses could not reveal any significant difference concerning
both the median OS and TTP between the older and the younger
patients. In addition, the proportion of patients that were treated
with prior adjuvant chemotherapy was higher in our study (almost
half of them) in comparison with other randomised trials with
FOLFIRI (Douillard et al, 2000; Tournigand et al, 2004). Therefore,
Table 2 Incidence of common toxicities with the FOLFIRI and FOLFOXIRI regimens (maximum toxicity per patient)
FOLFIRI (146) FOLFOXIRI (130) FOLFIRI (146) FOLFOXIRI (130)
Any Grade 3/4
%% P-value % % P-value
Neutropenia 60 73 NS
a 28 35 0.192
Febrile neutropenia 6 9 NS 4 7 0.186
Thrombocytopenia 20 31 NS 4 2 0.4
Anaemia 59 60 NS 1 4 0.072
Nause/vomiting 45 52 NS 4.8 4.6 0.944
Diarrhoea 51 69 NS 10.9 27.7 0.0001
Mucocitis 18 21 NS 4 5 0.748
Neurological 11 59 0.001 0 5.8 0.001
Cutaneous 15 21 NS 3 4 0.133
Alopecia 56 74 NS 12 32 0.0001
Fatigue 36 41 NS 5 5.6 0.944
aNS, nonsignificant.
Table 3 Second-line therapies
FOLFIRI FOLFOXIRI
Second-line treatment No patients % No patients % P-value
Any 102 70 80 58 0.041
L-OHP based 92 63 39 28 0.029
CPT-11 based 10 6 14 10 NS
a
Fluoropyrimidines 44 30 29 21 NS
Cetuximab 10 7 7 5 NS
aNS, nonsignificant.
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spatients’ characteristics could not be the reason for the improved
survival of patients treated with front-line FOLFIRI. Conversely,
the most possible explanation could be the administration of
second-line chemotherapy. Tournigand et al (2004) reported a
median OS of 21.5 months for patients treated with FOLFIRI
followed by second-line FOLFOX6 which was comparable with the
median OS of 21 months for the patients treated with FOLFIRI in
the present study. The proportion of patients treated with second-
line FOLFOX6 in the previous study (Tournigand et al, 2004) was
similar with the proportion of patients treated with L-OHP-based
chemotherapy (FOLFOX4 or XELOX) in the present study (74 and
63%, respectively). Overall the sequential treatment with FOLFIRI
and FOLFOX (or the opposite) should be considered as the
preferred treatment option, especially for the addition of molecular
targeted therapy. An alternative choice could be the combination
of CPT-11 and L-OHP without 5-FU, especially for patients that
can not tolerate treatment with infusional 5-FU (Goldberg et al,
2004).
In a recent meta-analysis, of seven phase III trials in advanced
CRC, it was shown that the median OS was significantly correlated
with the proportion of patients receiving all active agents over the
disease course but not with the proportion of patients receiving
second-line chemotherapy (Grothey et al, 2004). The results of the
present study seem to support this conclusion since the median OS
for the patients who did not receive second-line chemotherapy
after FOLFIRI failure was significantly lower compared with that of
patients who were treated with L-OHP-based second-line chemo-
therapy (12.5 vs 21 months, P¼0.016). In contrast, the median OS
did not differ in FOLFOXIRI arm for patients treated or not with
second-line chemotherapy (19.5 vs 23 months, P¼0.942). Taking
together these observations seem to indicate that patients who
were exposed to all three drugs presented a better median OS (420
months). Moreover, the survival of patients receiving all active
drugs upfront (FOLFOXIRI patients) was similar with that of
patients receiving the active drugs in sequence (i.e. FOLOFIRI first
and L-OHP-based regimen on progression). Conversely patients
who did not receive L-OHP during the evolution of the disease had
significantly lower median OS. However, we cannot exclude that
patients who lived longer had a better chance of receiving all
therapies and all available active drugs, while patients with poorer
and shorter life expectancy had a lesser chance to receive second-
line chemotherapy.
Another important finding of the present study was that patients
with PS of 2 presented a significantly lower median OS and TTP,
irrespectively of the used chemotherapy regimen. In addition, in
the multivariate analysis, PS of 2 was emerged as an independent
prognostic factor for disease progression and OS. Furthermore,
patients with PS of 2 experienced a significantly higher incidence
of neutropenia, febrile neutropenia, anaemia, diarrhoea and
fatigue in comparison with patients with a PS of 0–1 in both
treatment arms. Based on these data, it could be proposed that
patients with a PS of 2 would not be candidates for aggressive
combination chemotherapy. In contrast, patients X65 years did
not differ in any examined parameter except the significantly
higher incidence of diarrhoea complicating both regimens
compared with younger patients. These findings are in agreement
with two recently published phase II trials (Sastre et al,
2005; Souglakos et al, 2005) and strongly suggest that age
alone should not compromise the treatment decision in elderly
patients with advanced CRC. In addition, prior adjuvant
chemotherapy has not any significant effect in the patient’s
outcome (Table 2).
As expected, the FOLFOXIRI regimen had a less favourable
toxicity profile than FOLFIRI regimen. Patients treated with
FOLFOXIRI had a significantly higher incidence of severe
alopecia, diarrhoea and neurosensory toxicities compared
with patients treated with FOLFIRI; however, the death rates
within the first 60 days of treatment and the proportion of
toxic deaths were the same in both arms. Despite the observation
that the proportion of patients who discontinued treatment
was similar in the FOLFIRI (7%) and the FOLFOXIRI (12%) arms,
dose reductions and treatments delays were significantly more
frequent in the FOLFOXIRI arm resulting in lower dose intensity
rates.
In conclusion, the present study failed to demonstrate any
survival advantage of the FOLFOXIRI over the FOLFIRI regimen.
The improved OS of patients treated with front-line FOLFIRI and
especially for those who received second-line L-OHP-based
chemotherapy, emphasises the importance to treat with all the
available chemotherapeutic drugs (CPT-11, L-OHP, 5-FU) patients
with advanced CRC who are candidates for this type of therapy.
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